AJP - Renal Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Renal Physiol 291: F1248-F1254, 2006. First published June 27, 2006; doi:10.1152/ajprenal.00096.2006
0363-6127/06 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/6/F1248    most recent
00096.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Long, D. A.
Right arrow Articles by Johnson, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Long, D. A.
Right arrow Articles by Johnson, R. J.

Vascular endothelial growth factor administration does not improve microvascular disease in the salt-dependent phase of post-angiotensin II hypertension

David A. Long,1,2 Wei Mu,1 Karen L. Price,1 Carlos Roncal,1 George F. Schreiner,3 Adrian S. Woolf,2 and Richard J. Johnson1

1Section of Nephrology, Hypertension, and Transplantation, University of Florida, Gainesville, Florida; 2Nephro-Urology Unit, Institute of Child Health, University College London, London, United Kingdom; and 3Raven Biotechnologies, Incorporated, South San Francisco, California

Submitted 22 March 2006 ; accepted in final form 22 June 2006

Renal microvascular injury and tubulointerstitial inflammation may provide a potential mechanism for the development of salt-sensitive hypertension. Therefore, we hypothesized that vascular endothelial growth factor (VEGF) administration would prevent the development of salt-sensitive hypertension induced by ANG II. Infusion of ANG II in rats for 2 wk led to an elevation in blood pressure and an increase in blood urea nitrogen. Prominent tubular injury, focal areas of peritubular capillary loss accompanied by a decrease in urinary nitrites, thickening of the afferent arteriole, and an elevation in systemic and renal VEGF protein levels also occurred. In separate studies, animals were infused with ANG II and then placed on a low-salt diet for 1 wk. At this point, the animals were paired on the basis of weight and blood pressure and treated with either VEGF121 or vehicle subcutaneously for 8 wk while being fed a high-salt diet. During the treatment period, a spontaneous improvement in many parameters, including both renal function and healing of the peritubular capillaries, occurred to the same degree in both vehicle- and VEGF121-treated rats. VEGF121 significantly reduced blood pressure and accelerated the recovery of tubular injury. In contrast, vehicle-treated rats demonstrated a persistent increase in afferent arteriolar media-to-lumen ratio, which was further enhanced in rats treated with VEGF121. Therefore, VEGF therapy has only limited benefits on the healing of renal lesions in the salt-dependent phase of post-ANG II-mediated hypertension.

blood vessels; vascular growth factors



Address for reprint requests and other correspondence: D. A. Long, Nephro-Urology Unit, Institute of Child Health, Univ. College London, 30 Guilford St., London, WC1N 1EH, UK (e-mail: d.long{at}ich.ucl.ac.uk)




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
E. C. Leonard, J. L. Friedrich, and D. P. Basile
VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury
Am J Physiol Renal Physiol, December 1, 2008; 295(6): F1648 - F1657.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. Hagiwara, G. Bledsoe, Z.-R. Yang, R. S. Smith Jr., L. Chao, and J. Chao
Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress
Am J Physiol Renal Physiol, December 1, 2008; 295(6): F1735 - F1743.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
T. Nakagawa
Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease
Am J Physiol Renal Physiol, June 1, 2007; 292(6): F1665 - F1672.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.